# Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route

> **NCT01488188** · PHASE1 · COMPLETED · sponsor: **International Vaccine Institute** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Influenza vaccine
- **BIOLOGICAL:** Influenza vaccine

## Key facts

- **NCT ID:** NCT01488188
- **Lead sponsor:** International Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01488188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01488188, "Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01488188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*